Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
…
continue reading
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
…
continue reading
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
…
continue reading
This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. This is intended to be a supplement to other established board studying resources for busy trainees. *This podcast is intended to be an educational reso ...
…
continue reading
I used to think that being a good dad was all about managing the chaos. Providing, being a good husband, feeding the dogs, volunteering at school, and making sure the homework gets done. And, if you can do all that in a nice suburban neighborhood, you're probably really doing well. I checked these boxes on most days and figured I was doing alright. Then, on Nov. 1, 2015, my daughter Galia said "Dad, my leg hurts." I thought it was nothing; it turns out it was something. Acute Myeloid Leukemi ...
…
continue reading
America's first radio talk show dedicated to overcoming chronic pain. Hear exclusive interviews and personal stories from celebrity guests. No one is immune to pain, but together we can overcome it.
…
continue reading
HemeTalks: Conversations in Hematology Education is the latest podcast channel by the American Society of Hematology (ASH)! Explore educational content crafted by subject-matter experts from the ASH tailored to fulfill your professional education requirements. Whether you are a clinician or researcher, HemeTalks provides innovative education designed for every career stage and subspecialty.
…
continue reading
MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company. Podcasts are intended for licensed adul ...
…
continue reading
As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoke ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia
7:39
7:39
Play later
Play later
Lists
Like
Liked
7:39
A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of L…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
34:45
34:45
Play later
Play later
Lists
Like
Liked
34:45
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…
…
continue reading
This week’s episode will be focusing on infusion reactions - one of the most common calls we get as heme/onc fellows and high yield facts for new fellows as well as boards. We will go over the important details on mechanisms of infusion reaction, class of drugs that most commonly cause infusion reactions, treatment for infusion reactions, and when/…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Current Clinical Practice and NCCN Guidelines for CLL/SLL
31:33
31:33
Play later
Play later
Lists
Like
Liked
31:33
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…
…
continue reading
This week’s episode will be focusing on common topics both for new fellows & residents. We will go over the important details on some clinically important oncologic emergencies including brain metastases, hypercalcemia, cord compression and SVC syndrome.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma
1:00:49
1:00:49
Play later
Play later
Lists
Like
Liked
1:00:49
Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
28:35
28:35
Play later
Play later
Lists
Like
Liked
28:35
In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
24:23
24:23
Play later
Play later
Lists
Like
Liked
24:23
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
HPV Vaccination Prevents HIV-Related Cancers in Men
6:02
6:02
Play later
Play later
Lists
Like
Liked
6:02
HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated ca…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought
4:31
4:31
Play later
Play later
Lists
Like
Liked
4:31
Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden. Furthermore, the st…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers
6:28
6:28
Play later
Play later
Lists
Like
Liked
6:28
Patients who had immune-related adverse events had better responses and lived longer than those who didn’t. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting.OncTimesTalk reporter Pete…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
24:30
24:30
Play later
Play later
Lists
Like
Liked
24:30
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ASCO 2024 Plenary: ADRIATIC Trial in Limited Stage Small Cell Lung Cancer
12:26
12:26
Play later
Play later
Lists
Like
Liked
12:26
This week’s episode will discuss updates from ASCO 2024 next with the practice changing ADRIATIC trial presented by Dr. Spigel during the plenary: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC).
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for AML
25:21
25:21
Play later
Play later
Lists
Like
Liked
25:21
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
19:19
19:19
Play later
Play later
Lists
Like
Liked
19:19
In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis
1:00:06
1:00:06
Play later
Play later
Lists
Like
Liked
1:00:06
Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Tips for New Doctors (& A Few For New Attendings)
27:48
27:48
Play later
Play later
Lists
Like
Liked
27:48
In light of the new academic year today, we are so excited for this special episode, hosting Dr Shikha Jain, who is the founder of Women in Medicine & a GI oncologist, & involved with ASCO Women's Networking Center. She shares some of her tips for new doctors, and a few for new attendings.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival
9:02
9:02
Play later
Play later
Lists
Like
Liked
9:02
When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer
14:15
14:15
Play later
Play later
Lists
Like
Liked
14:15
Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it’s also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular. For the Oncology Times podcast, OncT…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes
10:53
10:53
Play later
Play later
Lists
Like
Liked
10:53
The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of N…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma
11:34
11:34
Play later
Play later
Lists
Like
Liked
11:34
A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Acute Myeloid Leukemia (AML) 2024 x Dr. Catherine Lai Part 2
17:29
17:29
Play later
Play later
Lists
Like
Liked
17:29
Today’s episode is an update on AML (acute myeloid leukemia). In Part 2 we discuss the treatment options for first-line, as well as relapsed/refractory disease. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia
9:25
9:25
Play later
Play later
Lists
Like
Liked
9:25
Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital,…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Acute Myeloid Leukemia (AML) 2024 x Dr. Catherine Lai Part 1
25:17
25:17
Play later
Play later
Lists
Like
Liked
25:17
Today’s episode is an update on AML (acute myeloid leukemia). In Part 1 we discuss the usual presentation, diagnostic work-up, and updates on the classification of AMLs. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma
6:52
6:52
Play later
Play later
Lists
Like
Liked
6:52
Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy
8:13
8:13
Play later
Play later
Lists
Like
Liked
8:13
Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+), human epidermal growth factor receptor-low (HER2-low), and HER2-ultralow breast cancer after endocrine therapy, show longer progression-free survival in comparison with standard chemotherapy. After a…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC
8:50
8:50
Play later
Play later
Lists
Like
Liked
8:50
New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progre…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer
11:34
11:34
Play later
Play later
Lists
Like
Liked
11:34
When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study r…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic
17:36
17:36
Play later
Play later
Lists
Like
Liked
17:36
An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the confe…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
12:15
12:15
Play later
Play later
Lists
Like
Liked
12:15
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Metastatic Melanoma 2024 x Dr. Mike Atkins Part 2
23:43
23:43
Play later
Play later
Lists
Like
Liked
23:43
Today’s episode is updating what you need to know regarding the treatment of metastatic melanoma. We are so honored to have Dr. Michael Atkins here with us today, who is the first author of the practice changing DREAMseq trial, and provides his expertise on this important topic.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences
1:16:45
1:16:45
Play later
Play later
Lists
Like
Liked
1:16:45
Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma
10:31
10:31
Play later
Play later
Lists
Like
Liked
10:31
The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group’s early findings of AZD1390, an inhibitor of ataxia telangiectasia …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC
8:21
8:21
Play later
Play later
Lists
Like
Liked
8:21
A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR An…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes
13:46
13:46
Play later
Play later
Lists
Like
Liked
13:46
A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, re…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
33:54
33:54
Play later
Play later
Lists
Like
Liked
33:54
Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Localized Melanoma 2024 x Dr. Mike Atkins Part 1
21:16
21:16
Play later
Play later
Lists
Like
Liked
21:16
Today’s episode is a 2024 update on what to know regarding the risk factors, diagnostic work-up, staging and treatment of localized melanoma. We are so honored to have Dr. Michael Atkins here with us today who is deputy director of the Georgetown Lombardi Comprehensive Cancer Center . He is an internationally recognized expert in the management of …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma
42:08
42:08
Play later
Play later
Lists
Like
Liked
42:08
Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.By Neil Love, MD
…
continue reading
This week’s episode will be focusing on the second part of genetic syndromes with risk of malignancy. Last week we covered Li Fraumeni, Lynch, FAP, BRCA ½ and Cowdens. This week we are going to cover the syndromes associated with RCC as well as MEN 1 and 2 and a few others.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic
17:35
17:35
Play later
Play later
Lists
Like
Liked
17:35
An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types. At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice Pre…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Exercise Deters Prostate Cancer Death & Progression
10:24
10:24
Play later
Play later
Lists
Like
Liked
10:24
Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Data from an intervention study reported at the AACR Annual Meeting 2024 are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or met…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers
9:31
9:31
Play later
Play later
Lists
Like
Liked
9:31
Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024. The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease pr…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia
1:02:06
1:02:06
Play later
Play later
Lists
Like
Liked
1:02:06
Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
25:55
25:55
Play later
Play later
Lists
Like
Liked
25:55
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…
…
continue reading
This week’s episode will be focusing on genetic syndromes with increased risk of malignancies. In Part 1 we discuss Li-Fraumeni, Lynch Syndrome, FAP, BRCA 1 and 2, and Cowden's syndrome.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
47:23
47:23
Play later
Play later
Lists
Like
Liked
47:23
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Metastatic Kidney Cancer x Uromigos 2024 UPDATES (Part 2)
29:28
29:28
Play later
Play later
Lists
Like
Liked
29:28
Today’s episode we will cover 2024 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series
1:01:09
1:01:09
Play later
Play later
Lists
Like
Liked
1:01:09
Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma
15:07
15:07
Play later
Play later
Lists
Like
Liked
15:07
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting. After…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection
12:50
12:50
Play later
Play later
Lists
Like
Liked
12:50
An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San …
…
continue reading